Marker Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
MRKR Nasdaq 2836 markertherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Marker Therapeutics, Inc.

Marker Therapeutics Announces $16.1 Million Private Placement - Dec 19th, 2024 1:06 pm
Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma - Dec 19th, 2024 1:05 pm
Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer - Dec 17th, 2024 12:00 pm
Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium - Dec 10th, 2024 1:30 pm
Marker Therapeutics Leads 3 Noteworthy US Penny Stocks - Dec 6th, 2024 1:07 pm
Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit - Nov 26th, 2024 4:00 pm
Marker Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Nov 17th, 2024 2:14 pm
Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates - Nov 14th, 2024 9:30 pm
US Penny Stocks To Consider In October 2024 - Oct 23rd, 2024 4:04 pm
Marker Therapeutics price target raised to $19 from $11 at Ladenburg - Oct 22nd, 2024 12:20 pm
AML cell therapy trials to watch in 2024 targeting GvHD - Sep 26th, 2024 6:33 pm
Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors - Aug 28th, 2024 12:00 pm
Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates - Aug 14th, 2024 8:30 pm
Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma - Aug 12th, 2024 11:00 am
Marker Therapeutics (NASDAQ:MRKR) shareholders are up 20% this past week, but still in the red over the last five years - Jul 18th, 2024 10:27 am
Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - May 15th, 2024 8:15 pm
Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies - Apr 8th, 2024 11:00 am
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results - Mar 25th, 2024 9:45 pm
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference - Mar 22nd, 2024 4:30 pm